DISCUSSION QUESTIONS 1. Suppose you were running a company that developed a COVID l 9 vaccine and your only goal was to maximize long-run prots. How would you handle pricing of your vaccine? How would you handle the underlying intellectual property? 2. Rather than supporting patent waivers, governments of wealthy countries could instead dramatically increase their spending on programs to buy vaccines and distribute them worldwide. Should they take that approach? Why or why not? 3 . IS there a \"right\" amount of prot for companies to make on their vaccines? If so, what is it? 4. Does the fact that governments provided much of the mding for vaccine development affect your views about how the intellectual property should be handled? Why or why not? . rn